Effect of oral semaglutide on cardiometabolic risk factors in overweight and obese individuals with or without diabetes: a systematic review and meta-analysis
Abstract
Background: Obesity is linked to cardiometabolic risk, and semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a promising option for weight and metabolic control. This systematic review and meta-analysis evaluated the effects of oral semaglutide, compared with placebo, on cardiometabolic risk factors in overweight and obese adults with or without diabetes.
Materials and methods: In this systematic review and meta-analysis, following PRISMA 2020 guidelines, PubMed, Embase, and Scopus were searched through 25 August 2025. Randomized controlled trials (RCT) with overweight and obese populations, with or without diabetes, were included. The treatment and control groups received oral semaglutide and placebo, respectively. Outcomes were cardiometabolic factors and adverse events at baseline and follow-up. We pooled data using a random-effects model to estimate changes in outcomes by reporting Estimated Treatment Difference (ETD) as mean difference. Subgroup analyses were conducted based on dosage and follow-up duration.
Results: Thirteen RCTs involving 26,284 participants met the criteria (52% received semaglutide). Female ratio of the semaglutide group was 30.1% and for the placebo group weas 33.3%. Compared with placebo, semaglutide showed significant reductions in body weight (ETD - 2.85 kg; 95% CI [- 4.03 to - 1.66]; p < 0.001), BMI (ETD - 0.66 kg/m²; 95% CI [- 0.95 to - 0.36]; p < 0.001), waist circumference (ETD - 1.79 cm; 95% CI [- 2.63 to - 0.95]; p <…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 26,284 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.